Form 4: Akebia Therapeutics Executive Sells Shares Under Pre-Arranged Trading Plan

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, sold 13,334 shares of common stock on June 4, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Richard C. Malabre, SVP, Chief Accounting Officer of Akebia Therapeutics, Inc. (AKBA), reported the sale of 13,334 shares of common stock.
• The transaction occurred on June 4, 2025, at a weighted average price of $3.53 per share, with prices ranging from $3.50 to $3.60.
• This sale was executed pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan, which was adopted by Mr. Malabre on December 12, 2024.
• Following this transaction, Mr. Malabre beneficially owns 266,914 shares of Akebia Therapeutics common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's under a Rule 10b5-1 plan mitigates any negative interpretation, suggesting it's for personal financial planning rather than a reaction to company-specific negative news.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a discretionary sale based on new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive in the company.

Risks

• While executed under a 10b5-1 plan, insider selling can sometimes be perceived negatively by investors, potentially leading to questions about management's long-term confidence, though this is mitigated by the pre-scheduled nature of the transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the Reporting Person on December 12, 2024.
• The shares were sold at prices ranging from $3.50 to $3.60 and the price reported reflects the weighted average sale price.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It is specific to Akebia Therapeutics, Inc. and its executive's personal financial planning.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, but the 10b5-1 plan context suggests it's not a signal of lack of confidence in the company's future.

Key Dates

Recommendation

Keywords

Akebia Therapeutics, AKBA, Form 4, insider trading, stock sale, Rule 10b5-1, Richard C. Malabre, Chief Accounting Officer